Immune checkpoint molecules expressed by melanoma cells like PD-L1 contributes to the impairment of the function of infiltrating CD8+T cells and immune evasion [5], which provides the molecular basis of anti-PD-1/PD-L1 immunotherapy and have gained unprecedented progress in improving the outcome of patients [6]. Here, CD8A is linked to melanoma.